Larvol Delta - Acumen-Pharmaceuticals-to-Present-Studies-on-Cost-Savings-Associated-with-Use-of-pTau217-Screening-Assay-in-Phase-2-ALTITUDEAD-Study-and-Sabirnetug-OligomerSelectivity-at-the-Alzheimers-Association-International-Conference-AAIC-2025

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://www.globenewswire.com/news-release/2025/07/10/3113163/0/en/Acumen-Pharmaceuticals-to-Present-Studies-on-Cost-Savings-Associated-with-Use-of-pTau217-Screening-Assay-in-Phase-2-ALTITUDE-AD-Study-and-Sabirnetug-Oligomer-Selectivity-at-the-Alz.html

Jul 10, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next